MedTrace Logo

Therapeutic Response of Cannabidiol in Rheumatoid Arthritis

NCT04911127 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2024-06-07

No results posted yet for this study

Summary

The study will randomly assign Rheumatoid Arthritis (RA) patients on stable RA therapy to either placebo or cannabidiol (CBD). The overall goal of this proposal is to examine the efficacy and safety of CBD treatment as adjunctive to the medical management of RA patients.

Conditions

Interventions

DRUG

200mg Cannabidiol by capsules twice daily

200mg twice daily via 50mg capsules

DRUG

400mg Cannabidiol by capsules twice daily

400mg twice daily via 50mg capsules

DRUG

Placebo capsules

MCT oil capsules as placebo for CBD

Sponsors & Collaborators

Principal Investigators

  • Ziva Cooper, PhD · University of California, Los Angeles

  • Veena Ranganath, MD, MS · University of California, Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-05
Primary Completion
2023-12-31
Completion
2023-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04911127 on ClinicalTrials.gov